Abstract Search

ea0028oc5.3 | Growth, tumours and pituitary | SFEBES2012

Long term experience of ¹³¹I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?

Sze Wing-Chiu , Murray Iain , Avril Norbert , Drake William , Akker Scott , Grossman Ashley , Plowman Nick , Druce Maralyn

Introduction: 131I-MIBG is a well-established treatment modality for patients with neuroendocrine tumours (NETs). Our centre has now accumulated over 10 years of experience with 131I-MIBG therapy, with long term data to evaluate effects on disease progress and other long term outcomes following therapy. Bone marrow effects of radionuclide therapy may include prolonged suppression, myelodysplasia or even frank leukaemia. Incidence is thought to be low, but...

0 shares

Endocrine Abstracts

Long term experience of ¹³¹I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?

BiosciAbstracts

Endocrine Abstracts

Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?

BiosciAbstracts

Long term experience of ¹³¹I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?